Adjusted Earnings Per Share Growth
Adjusted EPS for full-year 2025 was $1.27 versus $0.84 in 2024, representing approximately 51% growth driven by gross margin expansion, selling expense optimization, and disciplined G&A management.
Revenue Delivered Within Guidance
Full-year 2025 revenue was $1,490,000,000 and Q4 revenue was $370,000,000, both landing inside management's guidance ranges.
Core Gross Margin Expansion
Core Nu Skin gross margin finished 2025 at 77.4%, an improvement of ~80 basis points year over year; core Nu Skin Q4 gross margin was 77.6%, up 100 basis points versus the prior year.
Operating Margin and Expense Discipline
Adjusted operating margin improved to 6.7% for the year, up 140 basis points year over year. Q4 operating margin was 6.3%. Selling expense for the quarter improved to 35.5% from 37.1% a year ago (down ~160 basis points).
Strengthened Balance Sheet and Cash Flow
Ended Q4 with approximately $240,000,000 in cash and reduced outstanding debt to $224,000,000 (net cash position). Cash flow from operations for the year was $80,300,000.
Capital Return to Shareholders
Returned capital during the year including ~$11,000,000 in dividends and $20,000,000 in share repurchases; $142,300,000 of repurchase authorization remains.
Prism IO and Large Data Asset
Built a substantial intelligent-wellness data asset (nearly 400,000,000 carotenoid data points from 21,000,000 scans of >10,000,000 people and over 1,000,000,000 IoT-derived data points overall). Prism IO introduced late 2025 with a target to place >100,000 devices in 2026 and an aspiration to reach 10,000,000 households by 2030.
Emerging Market Momentum and Strategic Growth Initiatives
Continued momentum in Latin America and initiation of premarket operations in India (started mid-November) as part of a broader strategy to expand into high-potential emerging markets and scale RISE manufacturing capabilities.